ADCT-241 / ADC Therapeutics - LARVOL DELTA

Preclinical development of ADCT-241, a novel exatecan-based antibody-drug conjugate targeting PSMA for the treatment of prostate cancer (AACR 2025) - "In summary, ADCT‑241 is a novel, stable PSMA-targeting ADC that mediates potent and specific anti-tumor activity in mouse xenograft models and exhibits an excellent tolerability profile in rats and cynomolgus monkeys. The data presented support future clinical development of ADCT-241 for the treatment of prostate cancer indications."

Preclinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 (PRNewswire) - "ADC Therapeutics SA...announced abstracts detailing multiple preclinical programs have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025....Oral presentation to highlight preclinical investigation of Claudin-6 ADC in ovarian and NSCLC cancer models. Preclinical data for PSMA and ASCT2-targeted ADCs accepted for poster presentations."

Preclinical • Non Small Cell Lung Cancer • Ovarian Cancer • Prostate Cancer